Vistagen Therapeutics, Inc. filings document regulatory and corporate events for a Nasdaq-listed late clinical-stage biopharmaceutical company. Recent Form 8-K disclosures cover clinical program updates for fasedienol in the PALISADE social anxiety disorder program, FDA-related developments for refisolone under an IND application, and Regulation FD materials such as corporate presentations.
The company’s filings also record governance and capital-structure matters, including board departures, Audit Committee composition and Nasdaq listing-rule compliance, employee retention awards under the Amended and Restated 2019 Omnibus Equity Incentive Plan, and workforce and cash-management actions tied to clinical-development priorities.
Vistagen Therapeutics, Inc. (VTGN) filed a Form 4 disclosing an equity award to a senior executive. On 06/23/2025 the company granted its Chief Legal Officer, Reid G. Adler, a non-derivative stock option covering 100,000 shares of common stock at an exercise price of $1.96 per share. The award was issued under Vistagen’s Amended and Restated 2019 Equity Omnibus Incentive Plan.
The option vests in equal monthly installments over three years beginning on the grant date, resulting in full vesting on the three-year anniversary (06/23/2028), and carries a ten-year contractual term expiring 06/23/2035. Following this transaction Mr. Adler beneficially owns 100,000 derivative securities directly, and no open-market purchases or sales of common stock were reported. No 10b5-1 trading plan was indicated. The filing was signed by Cynthia Anderson, Attorney-in-Fact, on 06/25/2025.
Because the disclosure involves a routine incentive grant to a single officer with no immediate cash proceeds or share disposition, it is generally viewed as neutral to mildly positive from a governance standpoint: it aligns executive incentives with long-term shareholder value without altering the public float in the near term.
Vistagen Therapeutics (VTGN) President and CEO Shawn Singh received a significant stock option grant on June 23, 2025. The Form 4 filing discloses:
- Grant of 300,000 stock options to purchase common stock
- Exercise price set at $1.96 per share
- Options expire on June 23, 2035
- Vesting schedule: Equal monthly installments over 3 years starting from grant date
The stock options were granted under the company's Amended and Restated 2019 Equity Omnibus Incentive Plan. This equity compensation aligns the CEO's interests with shareholders through long-term vesting requirements. Singh serves as both President/CEO and Director of Vistagen Therapeutics.
Vistagen Therapeutics (Nasdaq: VTGN) filed an 8-K disclosing a C-suite change under Item 5.02.
- Elissa Cote, age 50, was appointed Chief Corporate Development Officer effective June 23 2025.
- Cote’s background includes senior strategy and BD roles at Mallinckrodt, Sucampo and MedImmune, plus advisory work since 2022.
- The Company executed a customary Indemnification Agreement with Cote, attached as Exhibit 10.1, requiring full indemnity and expense advancement to the maximum extent allowed by Nevada law.
- No related-party transactions or special arrangements were reported.
- Press release announcing the hire is filed as Exhibit 99.1.
No financial metrics were updated; the report is limited to leadership and governance matters.